<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088018</url>
  </required_header>
  <id_info>
    <org_study_id>VetsECS21</org_study_id>
    <nct_id>NCT05088018</nct_id>
  </id_info>
  <brief_title>Swallowable Cannabigerol Tablets for Sleep Quality In Veterans (Veterans Exploring Cannabigerol for Sleep)</brief_title>
  <acronym>ECS21</acronym>
  <official_title>A Placebo-controlled, Triple-blind, Pre-post Interventional Study of Swallowable Cannabigerol Tablets on Sleep Quality in Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chris Emerson</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veterans Cannabis Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Curebase</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Santa Cruz Veterans Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Metta Medical, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New methods for the treatment and support of Veterans experiencing sleep issues is critically&#xD;
      needed. LEVEL's unique, targeted effects-based cannabis products provide a unique opportunity&#xD;
      to study the therapeutic safety and efficacy of cannabigerol (a non-psychoactive cannabinoid)&#xD;
      with a controlled dosage. Study participants will participate in an interventional,&#xD;
      placebo-controlled, triple-blind pre-post study design. Participants will have a four-week&#xD;
      run-in phase followed by an eight-week treatment phase with a CBG ProtabTM or placebo&#xD;
      ProtabTM in a swallowable tablet form. During the study, participants will answer questions&#xD;
      assessing their sleep, alcohol and drug use, and quality of life, among others. They will&#xD;
      also wear a Fitbit Inspire 2 to collect biometric data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">January 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medical Outcomes Study (MOS) Sleep Problems Index II</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in sleep quality from baseline scores as measured by the Medical Outcomes Study (MOS) Sleep Problems Index II after 4 weeks. Scores range from 0-100, with higher scores indicating a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO-DAS-2.0-12</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in qualify of life from baseline scores on the World Health Organization Disability Assessment Schedule, Version 2.0 after 4 weeks. Scores range from 12-60, with higher scores indicating a worse outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleep Biometric Activity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in sleep Duration and quality from baseline to 4 weeks post-treatment, captured using a Fitbit Physical Activity Tracking Device</description>
  </other_outcome>
  <other_outcome>
    <measure>Activity Biometric Activity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in activity Duration and quality from baseline to 4 weeks post-treatment, captured using a Fitbit Physical Activity Tracking Device</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate Biometric Activity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in resting heart rate from baseline to 4 weeks post-treatment, captured using a Fitbit Physical Activity Tracking Device</description>
  </other_outcome>
  <other_outcome>
    <measure>Medical Outcomes Study (MOS) Sleep Problems Index II</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in sleep quality from baseline scores as measured by the Medical Outcomes Study (MOS) Sleep Problems Index II after 2 weeks' treatment. Scores range from 0-100, with higher scores indicating a worse outcome.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Active Cannabigerol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg daily swallowable Cannabigerol tablets for 2 weeks, immediately followed by 50 mg daily swallowable Cannabigerol tablets for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 mg daily swallowable placebo tablets for 2 weeks, immediately followed by 50 mg daily swallowable placebo tablets for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cannabigerol</intervention_name>
    <description>Cannabigerol is a non-psychoactive cannabinoid obtained from the cannabis plant.</description>
    <arm_group_label>Active Cannabigerol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo form of the same swallowable tablet with no cannabigerol</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Veteran status&#xD;
&#xD;
          -  MOS Sleep Problems Index II &gt; 30&#xD;
&#xD;
          -  California resident&#xD;
&#xD;
          -  Participants must own their own smartphone device to use for the study. Devices must&#xD;
             meet the following criteria:&#xD;
&#xD;
          -  Participants must be comfortable reading study instructions in English and&#xD;
             communicating with study team in English&#xD;
&#xD;
          -  Be willing to commit to study dosing, completing evaluation instruments, and following&#xD;
             study protocol activities.&#xD;
&#xD;
          -  If female and of childbearing potential, agree to use an effective form of birth&#xD;
             control during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If using sleep medications, medication and dosage have not been changed in the past&#xD;
             month and will remain unchanged for the duration of the study&#xD;
&#xD;
          -  If using other psychotropic medications, medication and dosage have not been changed&#xD;
             in the past 2 months, and will remain unchanged for the duration of the study&#xD;
&#xD;
          -  Prior observation that the prospective participant has stopped breathing or observed&#xD;
             choking/gasping during their sleep&#xD;
&#xD;
          -  Previous diagnosis of sleep apnea (participant reported)&#xD;
&#xD;
          -  Currently using a CPAP (or similar PAP device) for sleep apnea&#xD;
&#xD;
          -  Currently in a Cognitive Behavioral Therapy for Insomnia (CBTI) program&#xD;
&#xD;
          -  Women who are currently pregnant, trying to become pregnant, or breastfeeding&#xD;
&#xD;
          -  Currently using CBG on a regular basis&#xD;
&#xD;
          -  Participant has already participated in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>415.612.3779</phone>
    <email>ECS21@curebase.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virtual Site</name>
      <address>
        <city>Walnut</city>
        <state>California</state>
        <zip>91789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>415-634-7019</phone>
      <email>ECS21@curebase.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Metta Medical, Inc</investigator_affiliation>
    <investigator_full_name>Chris Emerson</investigator_full_name>
    <investigator_title>CEO &amp; Founder</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

